OBJECTIVES: To identify what was the influence of  cardiovascular drugs recommendations issued by AOTM in years 2005-2012 for the reimbursement decisions taken by Minister of Health (MoH). The main task of AOTM, established  in  2005, is to prepare recommendations on financing all medical technologies from public funds for the MoH. For all new health technologies entering market full pharmacoeconomic evaluations are required before the reimbursement decisions are taken by MoH METHODS: Among recommendations of AOTM published until the end of 2012 we analyzed all related to cardiovascular drugs. The recommendations were identified and categorized into types of recommendations (positive or negative). We compared the outcomes with reimbursement list officially published by MoH (January 2013). RESULTS: Among 753 documents (recommendations, opinions, statements) issued by AOTM, only 38 (5%) applied to innovative, cardiovascular drugs. AOTM issued positive recommendations for reimbursement to 22 of 38 of cardiovascular drug submissions (58%). 16 of 38 (42%) were not approved and received negative recommendations. Having analyzed the reimbursement list we realized that only 10 of 38 (26%) drugs assessed by AOTM are occurred on the reimbursement list. 9 of 10 drugs(90%) were positive  recommended by AOTM. Only 1 drug (10%) was assessed negative. CONCLUSIONS: The influence of recommendations issued by AOTM for cardiovascular drugs for reimbursement decisions taken by MOH  were not significant with respect to place the drugs on the list. But we can realize that only 1 drug with negative AOTM recommendation exists on  the list. The conclusion indicates that the medicine with negative recommendations probably will not be accepted (in 90%) for reimbursement from public sources. Contrarily,  not every drug with positive recommendation issued by AOTM will be placed on the reimbursement list.